Axsome Survey Highlights Late Recognition of Alzheimer’s Agitation Symptoms
Event summary
- Axsome Therapeutics presented survey results at Psych Congress 2026 showing 97% of caregivers reported agitation negatively impacted Alzheimer’s patients' quality of life.
- 76% of caregivers wished they had recognized agitation symptoms sooner, highlighting a delay in treatment.
- 89% of caregivers wanted easier ways to track agitation symptoms, and 81% sought better communication tools with healthcare providers.
- Survey conducted by The Harris Poll with 751 caregivers, sponsored by Axsome and in collaboration with CaringKind.
The big picture
Axsome’s survey underscores the critical gap in early detection of Alzheimer’s agitation, a condition affecting up to 75% of patients. The findings position Axsome to emphasize the need for earlier intervention, aligning with broader industry trends toward personalized and proactive dementia care. The company’s focus on caregiver insights could strengthen its market position in a competitive neuroscience landscape.
What we're watching
- Treatment Timing
- How earlier recognition of agitation symptoms will impact treatment outcomes for Alzheimer’s patients.
- Caregiver Tools
- Whether Axsome can develop and commercialize tools to help caregivers track and communicate agitation symptoms.
- Market Opportunity
- The pace at which Axsome can leverage these insights to differentiate its Alzheimer’s agitation treatments.